Skip to main content
Medical information Clinical review pending

Cytogenetics

IHC Extended Panel 10 Markers

The IHC Extended Panel 10 Markers test analyzes tissue samples for 10 specific genetic markers, aiding in cancer diagnosis, treatment planning, and monitoring.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Formalin-fixed paraffin-embedded (FFPE) tissue block or formalin-fixed tissue.
Results
Confirm with the laboratory before booking.
Preparation
Confirm with the laboratory before booking. Your doctor will advise on necessary preparations.
Test priceKSh 19,500

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the IHC Extended Panel 10 Markers test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of specific cancer types
  • ✓Prognosis assessment in cancer patients
  • ✓Guiding targeted cancer therapy
  • ✓Monitoring response to cancer treatment
  • ✓Identifying potential therapeutic targets
02

In plain language

What this test helps you understand

This test helps identify specific genetic markers in tumor tissue, aiding in cancer diagnosis, prognosis, and guiding treatment decisions.
The IHC Extended Panel 10 Markers test is a specialized diagnostic tool used primarily in oncology to analyze tissue samples for specific genetic markers. This test plays a crucial role in identifying cancer types, assessing treatment responses, and guiding therapeutic decisions.

This test measures the expression of 10 key markers in tissue samples that are preserved in 10% Neutral Buffered Formalin or as a paraffin block. These markers provide insights into the genetic profile of tumors, which is essential for accurate diagnosis and personalized treatment plans.

Taking the IHC Extended Panel 10 Markers test offers numerous advantages, including accurate identification of cancer types through genetic profiling, informed decision-making regarding treatment options, monitoring of treatment efficacy and disease progression, and enabling a personalized medicine approach for better patient outcomes.

Results from the IHC Extended Panel 10 Markers test are typically available within 5 days. A healthcare professional will help interpret these results, explaining the significance of each marker and how they relate to your specific condition. Understanding these results is crucial for making informed decisions about your health and treatment options.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. Your doctor will advise on necessary preparations.
SampleFormalin-fixed paraffin-embedded (FFPE) tissue block or formalin-fixed tissue.
MethodologyImmunohistochemistry (IHC) using specific antibodies to detect the presence and expression level of 10 target markers in tissue sections.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
Test results are dependent on the quality of the tissue sample provided. Interpretation requires correlation with clinical findings and other diagnostic tests. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

IHC stands for Immunohistochemistry. It is a laboratory technique that uses antibodies to detect specific proteins (markers) in tissue samples.
Testing for multiple markers provides a more comprehensive profile of the tumor's characteristics, aiding in accurate diagnosis and treatment planning.
The sample is typically a tissue biopsy or surgical resection specimen, preserved in formalin and processed into a paraffin block.
A pathologist or oncologist will interpret the IHC results in the context of your clinical history and other diagnostic findings.
Yes, a doctor's prescription is required to order this test.
Results are typically available within 5 days, but confirm with the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp